RECURRENT OSTEOSARCOMA
Clinical trials for RECURRENT OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1 to 21) whose cancers had come back or did not respond to standard treatment. The drug works by blocking certain proteins that help cancer cells grow. The goal was to see if the drug could shrink t…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:11 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Promising drug combo shows potential for tough childhood cancers
Disease control CompletedThis early-stage trial tested a combination of two drugs, magrolimab and dinutuximab, in 12 children and young adults with neuroblastoma or osteosarcoma that had come back or stopped responding to treatment. The main goals were to find the safest dose and see if the combination c…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in early trial
Disease control CompletedThis study tested a drug called samotolisib in 18 children and teens whose cancers (solid tumors, lymphoma, or related disorders) had spread, returned, or stopped responding to treatment. Only those with specific gene mutations (TSC or PI3K/MTOR) were eligible. The goal was to se…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC